Wolfe Research raises Vertex stock price target on CF franchise value
Covered in this story
What has happened since
- Vertex Pharmaceuticals is down 3.8% since this was published, 56 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Wolfe Research’s $562 target on $VRTX is on the record and being tracked to Aug 2027 (12-month default), scored on the close that day.
Wolfe Research’s track record →Call it yourself
No member calls on $VRTX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Vertex Pharmaceuticals →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.